HUTCHMED (China) (HCM) Common Equity (2014 - 2025)
HUTCHMED (China)'s (HCM) quarterly Common Equity came in at $159.2 million in Q4 2025, up 62.83% year-on-year from $97.8 million in Q4 2024, and down 87.05% on a QoQ basis from $1.2 billion in Q2 2025.
HUTCHMED (China) (HCM) Common Equity (2014 - 2025) Analysis & Trends
HUTCHMED (China) (HCM) has 12 years of Common Equity data on file, last reported at $159.2 million in Q4 2025.
- On a quarterly basis, Common Equity rose 62.83% year-over-year to $159.2 million in Q4 2025; TTM through Dec 2025 was $159.2 million, a 62.83% increase from a year earlier, with the FY2025 full-year figure at $159.2 million, up 63.43% from the prior year.
- Common Equity for Q4 2025 stood at $159.2 million, down from $1.2 billion in the prior quarter.
- Over the last five years, Common Equity for HCM reached as high as $93.5 billion in Q4 2023 and fell as low as $78.0 million in Q4 2022.
- Historically, Common Equity has averaged $9.0 billion across 5 years, with a median of $740.1 million in 2024.
- Across the five-year window, Common Equity jumped 119722.09% in 2023 and slumped 99.9% in 2024, its largest moves.
- Year by year, Common Equity stood at $126.7 million in 2021, then slumped by 38.41% to $78.0 million in 2022, then soared by 119722.09% to $93.5 billion in 2023, then slumped by 99.9% to $97.8 million in 2024, then jumped by 62.83% to $159.2 million in 2025.
- Per Business Quant data, the three most recent Common Equity figures were $159.2 million in Q4 2025, $1.2 billion in Q2 2025, and $97.8 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 21.93 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.23 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 3.23 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 47.38 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 5.90 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 56.13 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 3.41 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.50 Bn |
| 10 | HUTCHMED (China) | 241.90 Mn | 243.61 Mn | - | 159.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 159.17 Mn |
| Jun 30, 2025 | 1.23 Bn |
| Dec 31, 2024 | 97.75 Mn |
| Jun 30, 2024 | 740.08 Mn |
| Dec 31, 2023 | 93.50 Bn |
| Jun 30, 2023 | 800.02 Mn |
| Dec 31, 2022 | 78.03 Mn |
| Jun 30, 2022 | 851.85 Mn |
| Dec 31, 2021 | 126.69 Mn |
| Jun 30, 2021 | 1.01 Bn |
| Mar 31, 2021 | 428.27 Mn |
| Dec 31, 2020 | 152.71 Mn |
| Jun 30, 2020 | 367.05 Mn |
| Sep 30, 2019 | 337.79 Mn |
| Jun 30, 2019 | 373.04 Mn |
| Mar 31, 2019 | 400.36 Mn |
| Dec 31, 2018 | 412.26 Mn |
| Jun 30, 2018 | 457.85 Mn |
| Dec 31, 2017 | 461.73 Mn |
| Jun 30, 2017 | 211.50 Mn |